{
  "id": 641311,
  "title": "William Blair downgrades Cardiff Oncology stock rating on rights uncertainty",
  "url": "https://urgent.news/2026/08/12/william-blair-downgrades-cardiff-oncology-stock-rating-on-rights",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-12T07:14:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/william-blair-downgrades-cardiff-oncology-stock-rating-on-rights-uncertainty-93CH-4853795"
  },
  "original_language": "en",
  "account": "William Blair recently reduced its stock rating for Cardiff Oncology (NASDAQ: CRDF) to Market Perform from Outperform. This follows the company's second-quarter financial report and business update, released after the market close on August 11. William Blair claims that the company's fundamentals have significantly worsened. A major concern cited by the firm is the uncertainty surrounding onvansertib rights. This uncertainty is evident in the stock's performance, with shares plummeting 63% year-to-date to $1.05 per share. InvestingPro data also highlights that Cardiff is rapidly depleting its cash reserves, with a levered free cash flow of -$37.46 million over the past year. The firm warns that Cardiff must secure additional funding before commencing a Phase III trial. This financial strain contributes to an unfavorable risk/reward ratio, leading to the downgrade. Despite these challenges, InvestingPro analysis suggests that the stock is currently undervalued, with a fair value estimate of $1.29 per share. Cardiff Oncology has recently announced a $10 million registered direct offering, selling 8,571,429 shares and associated warrants at $1.05 each. Company insiders and directors have also bought shares at $1.435 per share. Cardiff also reported positive Phase 2 trial results for onvansertib combined with standard treatments in metastatic colorectal cancer. However, the company faces additional hurdles due to H.C. Wainwright downgrading its stock to Neutral after Nerviano Medical Sciences terminated a crucial license agreement, citing alleged patent inventorship breaches. Likewise, TD Cowen reduced its rating to Hold due to the ongoing license dispute. Cardiff Oncology intends to host an investor webcast to share updated trial data, to be presented at the American Society of Clinical Oncology Annual Meeting.",
  "summary": "William Blair recently downgraded Cardiff Oncology's stock rating to Market Perform from Outperform due to deteriorating fundamentals and uncertainty surrounding onvansertib rights. The firm highlighted Cardiff's negative cash flow and need to raise additional capital before initiating a Phase III study. Despite reporting positive results from its Phase 2 clinical trial for RAS-mutated metastatic colorectal cancer, Cardiff faces challenges from H.C. Wainwright and TD Cowen downgrading their stock ratings due to a termination of a key license agreement. Cardiff Oncology plans to host an investor webcast to discuss updated trial data at the American Society of Clinical Oncology Annual Meeting.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}